Merck
MRK | NYSE
$144.46
-$3.30 (-2.23%)
At close: Nov 16, 2026, 4:02 PM ET
$144.85
+$0.39 (+0.27%)
After-hours:
Nov 16, 2026, 7:51 PM ET
Merck Company Profile
Company profile explainedCompany Profile
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
Key Executives
| Name | Position |
|---|---|
| Robert Davis | Chairman, President & Chief Executive Officer |
| Caroline Litchfield | Executive Vice President & Chief Financial Officer |
| Betty D. Larson | Executive Vice President & Chief Human Resources Officer |
| Chirfi Guindo | Executive Vice President of Strategic Access, Policy & Communications |
| Dalton E. Smart | Senior Vice President of Finance, Principal Accounting Officer & Global Controller |
| David Michael Williams | Executive Vice President and Chief Information & Digital Officer |
| Dean Y. Li | Executive Vice President & President of Merck Research Laboratories |
| Gaurav K. Gupta | Executive Vice President and Chief Information & Digital Officer |
| Jennifer L. Zachary | Executive Vice President & General Counsel |
| Johannes J. Oosthuizen | Executive VP and President of Oncology & MSD International |
| Peter Dannenbaum | Vice President of Investor Relations |
| Richard R. DeLuca Jr. | Executive Vice President & President of Merck Animal Health |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 29, 2026 | 8-K | Current Report |
| Oct 22, 2026 | 3/A | [Amend] Filing |
| Oct 15, 2026 | 25-NSE | Filing |
| Oct 13, 2026 | 8-K | Current Report |
| Oct 01, 2026 | 4 | Filing |
| Oct 01, 2026 | 4 | Filing |
| Oct 01, 2026 | 4 | Filing |
| Sep 01, 2026 | 3 | Filing |
| Aug 13, 2026 | 4 | Filing |
| Aug 13, 2026 | 4 | Filing |
Merck
| Country | United States |
| IPO Date | Jan 13, 1978 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 74,000 |
| CEO | Robert Davis |
Contact Details
126 East Lincoln Avenue Rahway,
New Jersey 07065 United States
Stock Details
| Ticker Symbol | MRK |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000310158 |
| CUSIP Number | 58933Y105 |
| ISIN Number | US58933Y1055 |
| SIC Code | 2834 |
Recent News
- 11 hours ago / fool.comIs Merck's Stock Still a Good Buy at $150?
- 2 days ago / 247wallst.comHe Has Had Surgery for Melanoma and Is Terrified the Cancer Will Return. A New Vaccine Kept 82% of Trial Patients Cancer-Free for Two Years, but Medicare Won’t Pay for Experimental Treatment
- 3 days ago / businesswire.comMerck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season
- 3 days ago / businesswire.comMerck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) in Combination With Lenvatinib for Adults With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) Following Treatment With an Anti-PD-1/PD-L1 Therapy
- 4 days ago / marketbeat.comWhat Merck KGaA (MRK) Said on Its Q3 Earnings Call
- 6 days ago / businesswire.comFDA Approves PIMJETMI® (pimicotinib) for Patients with Tenosynovial Giant Cell Tumor
- 8 days ago / businesswire.comMerck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 Fibrosis
- 8 days ago / zacks.comMRK's 2027 Outlook Challenging, Long-Term Prospects Promising
- 9 days ago / 247wallst.comTwo 70-Year-Olds Will Start the Same $12,272 Keytruda Qlex Cancer Injections. One With Medigap Plan G Will Owe $0 in Coinsurance After the Part B Deductible, While the Other Will Owe 20% With No Annual Cap
- 10 days ago / zacks.comMerck Stock Shows Sustained Strength: Time to Buy, Sell or Hold?
Add to Watchlist
Select watchlists to add or remove MRK